secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alaunos Therapeutics, Inc. (TCRT)
CIK:        0001107421
Form:       8-K
Filed at:   2026-01-08T23:59:59+00:00
Accession:  0001193125-26-007054
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 3.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alaunos reports positive preclinical obesity data but cash runway only through Q1 2026
--------------------------------------------------------------------------------

- Preclinical DIO mouse study shows statistically significant dose-related weight loss and improved body composition; lead compound identified.
- Cash and equivalents ~$1.9M as of Sep 30, 2025; runway only through Q1 2026; plans additional financing by end of Q1 2026.
- Shareholder group with 8.6% stake requests Gerald W. Bruce as director; Corporate Governance Committee to review.
- Terminated engagement with Cantor Fitzgerald as financial advisor; no fees paid, no strategic transaction consummated.
- Amended bylaws with stockholder nomination advance notice requirements and universal proxy rule compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526007054/0001193125-26-007054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1107421/000119312526007054/tcrt-20260108.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-007054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer